LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Stock List・CareDx Inc

CareDx Inc

Closed

SectorHealthcare

21.28 -0.61

Buy Sell

Overview

Share price change

24h

Current

Min

21.04

Max

21.96

Key metrics
By Trading Economics
Income	6.9M 2.8M
Sales	9.3M 118M
P/E Sector Avg	14.645 49.8
EPS	0.34
Profit margin	2.387
Employees	761
EBITDA	5.6M 7.1M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+14.76% upside

Dividends
By Dow Jones
Next Earnings	5 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-36M 1.1B
Previous open	21.89
Previous close	21.28

News Sentiment

By Acuity

59%

41%

284 / 346 Healthcare

Technical Score

By Trading Central

Confidence

Neutral Evidence

14.77 / 18.49 Support & Resistance

CareDx Inc Chart

Past performance is not a reliable indicator of future results.

Related News

12 May 2026, 22:50 UTC

Earnings

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 May 2026, 22:49 UTC

Earnings

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 May 2026, 22:32 UTC

Earnings

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 May 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 May 2026, 22:57 UTC

Market Talk

Earnings

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 May 2026, 22:26 UTC

Earnings

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 May 2026, 22:25 UTC

Earnings

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 May 2026, 22:25 UTC

Earnings

Aristocrat Leisure Interim Dividend A$0.50/Security

12 May 2026, 22:24 UTC

Earnings

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 May 2026, 22:23 UTC

Earnings

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 May 2026, 22:23 UTC

Earnings

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 May 2026, 22:19 UTC

Earnings

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 May 2026, 22:14 UTC

Earnings

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 May 2026, 22:14 UTC

Earnings

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 May 2026, 22:13 UTC

Earnings

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 May 2026, 22:12 UTC

Earnings

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 May 2026, 22:12 UTC

Earnings

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 May 2026, 22:11 UTC

Earnings

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 May 2026, 22:11 UTC

Earnings

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 May 2026, 22:10 UTC

Earnings

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 May 2026, 22:09 UTC

Earnings

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 May 2026, 22:09 UTC

Earnings

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 May 2026, 22:08 UTC

Earnings

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 May 2026, 22:07 UTC

Earnings

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 May 2026, 22:06 UTC

Earnings

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 May 2026, 22:06 UTC

Earnings

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 May 2026, 22:05 UTC

Earnings

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 May 2026, 22:04 UTC

Earnings

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 May 2026, 22:04 UTC

Earnings

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 May 2026, 22:04 UTC

Earnings

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Peer Comparison

Price change

CareDx Inc Forecast

Price Target

By TipRanks

14.76% upside

12 Months Forecast

Average 24.73 USD 14.76%

High 28 USD

Low 21 USD

Based on 6 Wall Street analysts offering 12 month price targets forCareDx Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to CareDx Inc - Dist in the past 3 months.

Technical Score

By Trading Central

14.77 / 18.49Support & Resistance

The bullish and bearish events are balanced.

All events are bearish.

Bearish events outweigh bullish events.

Sentiment

By Acuity

284 / 346 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.